HC Wainwright Has Optimistic Outlook of VRCA FY2028 Earnings

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) – HC Wainwright lifted their FY2028 EPS estimates for Verrica Pharmaceuticals in a research note issued to investors on Tuesday, April 8th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings per share of $0.11 for the year, up from their prior forecast of $0.06. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Verrica Pharmaceuticals’ current full-year earnings is ($1.46) per share. HC Wainwright also issued estimates for Verrica Pharmaceuticals’ FY2029 earnings at $0.18 EPS.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. The firm had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $1.30 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%.

Separately, Needham & Company LLC reissued a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $9.50.

Verrica Pharmaceuticals Stock Down 20.1 %

VRCA opened at $0.46 on Wednesday. Verrica Pharmaceuticals has a 52 week low of $0.38 and a 52 week high of $11.41. The business has a fifty day simple moving average of $0.60 and a 200-day simple moving average of $0.88. The firm has a market cap of $42.48 million, a P/E ratio of -0.25 and a beta of 1.68.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several institutional investors have recently modified their holdings of VRCA. Invesco Ltd. acquired a new stake in shares of Verrica Pharmaceuticals in the fourth quarter valued at $32,000. Barclays PLC raised its position in Verrica Pharmaceuticals by 404.6% in the 3rd quarter. Barclays PLC now owns 31,341 shares of the company’s stock valued at $45,000 after purchasing an additional 25,130 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in shares of Verrica Pharmaceuticals in the 3rd quarter valued at about $87,000. Verition Fund Management LLC acquired a new position in shares of Verrica Pharmaceuticals during the third quarter worth about $89,000. Finally, Jane Street Group LLC increased its stake in shares of Verrica Pharmaceuticals by 106.5% during the third quarter. Jane Street Group LLC now owns 69,872 shares of the company’s stock worth $101,000 after buying an additional 36,028 shares during the period. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.